TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30406392

Group type: EXPERIMENTAL
Intervention: Rifaximin (400 mg thrice/day for 2 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 27740850

Group type: EXPERIMENTAL
Intervention: Antiperspirant
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sunscreen B (inorganic physical sun block)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sunscreen A (organic chemical sun filter)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No lotion
Number of subjects: 20
Study: 24263176

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 100 mg twice daily for 28 days
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 100 mg twice daily for 28 days (excluding minimal to no baseline aggression)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (excluding minimal to no baseline aggression)
Number of subjects: 76
Study: 23449748

Group type: EXPERIMENTAL
Intervention: Astaxanthin 4-mg capsules + splinting
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo + splinting
Number of subjects: 63
Study: 20169378

Group type: EXPERIMENTAL
Intervention: Classical massage (biweekly 30‐min sessions for 5 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 34
Study: 18395477

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10mg-80mg) for 6 months
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (52 age- and sex-matched healthy individuals)
Number of subjects: 97
Study: 15359265

Group type: EXPERIMENTAL
Intervention: Topical ketorolac (0.5%)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 37
Study: 12432669

Group type: EXPERIMENTAL
Intervention: Listening to preferred music while out of restraints
Number of subjects: 40

Group type: COMPARATOR
Intervention: No music while out of restraints
Number of subjects: 40
Study: 10933357

Group type: EXPERIMENTAL
Intervention: Bladder distention in group 1 (no pretreatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bladder distention in group 2 (pretreatment with doxazosin, 2 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nitroglycerin administration after bladder distention
Number of subjects: 40
Study: 8661952

Group type: EXPERIMENTAL
Intervention: AAA Ca (900 mg/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Calcium carbonate (900 mg/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: COMPARATOR
Intervention: AAA Ca (after switching from placebo)
Number of subjects: 58
Study: 1645104

Group type: EXPERIMENTAL
Intervention: 0.32 mg/70 kg triazolam
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (lactose-filled capsules)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Novel visual stimulus in the context of placebo
Number of subjects: 4
Study: 6387488

Group type: EXPERIMENTAL
Intervention: Daily administration of an agonist of gonadotropin‐releasing hormone
Number of subjects: 8
Study: 30715168

Group type: EXPERIMENTAL
Intervention: pemetrexed and a platinum-based chemotherapy (cisplatin or carboplatin) plus 200 mg of pembrolizumab every 3 weeks for 4 cycles, followed by pembrolizumab for up to a total of 35 cycles plus pemetrexed maintenance therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: carboplatin or cisplatin with pemetrexed and atezolizumab followed by maintenance pemetrexed and atezolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: atezolizumab/carboplatin/nab-P
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: carboplatin/nab-P
Number of subjects: 0

Group type: COMPARATOR
Intervention: nab-PC regimen
Number of subjects: 0
Study: 29177501

Group type: COMPARATOR
Intervention: Prilocaine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Prilocaine + Bupivacaine
Number of subjects: 400
Study: 27824231

Group type: EXPERIMENTAL
Intervention: FITSTART intervention
Number of subjects: 331

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 331
Study: 1358830

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 22068424

Group type: EXPERIMENTAL
Intervention: Easy Vax™ dermal electroporation system (administered in two areas, total of six doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Easy Vax™ dermal electroporation system (administered in deltoid regions only after initial complaints)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Easy Vax™ dermal electroporation system (measured electrical properties of the skin)
Number of subjects: 10
Study: 21118176

Group type: EXPERIMENTAL
Intervention: Short program of medium intensity physical training (45-60 min, 3 times/week, 50-60% of VEM-test workload)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Short program of medium intensity physical training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (standard therapy for EVI treatment of IHD)
Number of subjects: 100
Study: 18509971

Group type: COMPARATOR
Intervention: Treatment 1: Oral MgSO4 solution before operation, Cefradine 2.0 g (I.V.) during anesthesia induction, followed by two doses of Cefradine 2.0 g and 0.5% Metronidazole 100 ml at 12-hour intervals for 24 hours post-operation.
Number of subjects: 165

Group type: COMPARATOR
Intervention: Treatment 2: Same as Treatment 1, but antibiotics continued for 3-5 days post-operation.
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control: Oral antibiotics 2-3 days before operation.
Number of subjects: 165
Study: 15974371

Group type: EXPERIMENTAL
Intervention: STEP program (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12687748

Group type: EXPERIMENTAL
Intervention: Aggressive exchange transfusion
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conservative (simple) transfusion
Number of subjects: 39
Study: 10588553

Group type: EXPERIMENTAL
Intervention: Double injection (group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single injection (group 1)
Number of subjects: 50
Study: 8676720

Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 185

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 185
Study: 1873582

Group type: EXPERIMENTAL
Intervention: Stomatognathic treatment and biofeedback therapy
Number of subjects: 32
Study: 6385318

Group type: EXPERIMENTAL
Intervention: HFJV/CPAP + IMV (1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HFJV/CPAP + IMV (2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: HFJV/CPAP
Number of subjects: 16
Study: 31842784

Group type: EXPERIMENTAL
Intervention: Robotic-assisted/standard laparoscopic rectal cancer surgery after 8 weeks
Number of subjects: 340

Group type: COMPARATOR
Intervention: Robotic-assisted/standard laparoscopic rectal cancer surgery after 12 weeks
Number of subjects: 340
Study: 30899948

Group type: EXPERIMENTAL
Intervention: ERAS nursing after operation
Number of subjects: 90
Study: 26879276

Group type: EXPERIMENTAL
Intervention: Ozanimod 0.5 mg
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Ozanimod 1 mg
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 24585721

Group type: EXPERIMENTAL
Intervention: TAC + zoledronic acid (ZA) 4 mg i.v. every 3 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: TAC (docetaxel, adriamycin, and cyclophosphamide)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: TAC + ZA
Number of subjects: 96

Group type: COMPARATOR
Intervention: TAC
Number of subjects: 96
Study: 23128568

Group type: EXPERIMENTAL
Intervention: Values-affirmation exercise
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control exercise
Number of subjects: 99
Study: 20573081

Group type: EXPERIMENTAL
Intervention: Aclidinium 50 microg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aclidinium 300 microg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aclidinium 600 microg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17426604

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) (N=10)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) (N=12)
Number of subjects: 22
Study: 17556612

Group type: EXPERIMENTAL
Intervention: Multivitamins (B, C, and E)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Vitamin A and beta-carotene (VA/BC)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Multivitamins including VA/BC
Number of subjects: 829

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 829
Study: 15562085

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 50
Study: 11287020

Group type: EXPERIMENTAL
Intervention: 0.0625 mg/d GnRH antagonist
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: 0.125 mg/d GnRH antagonist
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: 0.25 mg/d GnRH antagonist
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: 0.5 mg/d GnRH antagonist
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: 1.0 mg/d GnRH antagonist
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: 2.0 mg/d GnRH antagonist
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: FSH levels
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Late follicular phase LH, AD, and E(2) levels
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Late follicular phase E(2) levels
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Increasing GnRH antagonist doses
Number of subjects: 329
Study: 9103484

Group type: EXPERIMENTAL
Intervention: Nandrolone phenylpropionate (group 1, n = 7)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (group 2, n = 6) injected into gluteal muscle in 4 ml of arachis oil
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (group 3, n = 5) in 1 ml of arachis oil injected into gluteal muscle
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (group 4, n = 5) in 1 ml of arachis oil injected into deltoid muscle
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate 1-ml gluteal injection
Number of subjects: 23
Study: 7799411

Group type: EXPERIMENTAL
Intervention: Urease test for Helicobacter pylori detection
Number of subjects: 244
Study: 3733274

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g i.v.) with frusemide (40 mg p.o.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ceftriaxone (2 g i.v.) with placebo
Number of subjects: 12
Study: 31142636

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 50
Study: 28417592

Group type: EXPERIMENTAL
Intervention: Allopurinol (50-700 mg daily)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Nomogram based on allopurinol dose-response relationship
Number of subjects: 81
Study: 25176167

Group type: EXPERIMENTAL
Intervention: Citalopram plus psychotherapy treatment for the depressed cohort
Number of subjects: 67

Group type: COMPARATOR
Intervention: Citalopram treatment
Number of subjects: 67
Study: 23649140

Group type: EXPERIMENTAL
Intervention: 2000 IU Vitamin D (Group A)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 1000 IU Vitamin D (Group B)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 500 IU Vitamin D (Group C)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (Group D)
Number of subjects: 4
Study: 21885884

Group type: EXPERIMENTAL
Intervention: Daily weather conditions (temperature, rainfall, snowfall, daylight hours)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Weather conditions
Number of subjects: 241
Study: 19468961

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied to PC 3 using a 5-V pulse at 10 Hz for 15 minutes.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-meridian control area (no EA applied).
Number of subjects: 24
Study: 16705847

Group type: EXPERIMENTAL
Intervention: Acupuncture plus point-injection at points Quchi (LI11), Xuehai (SP10), Zusanli (ST36), Sanyinjiao (SP6), and Fengchi (GB20) plus point-injection at Zusanli (ST36) and Quchi (LI11)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Antihistamines (Acrivastine, Cinnarizine, Ranitidine)
Number of subjects: 64
Study: 15346264

Group type: COMPARATOR
Intervention: Thalidomide monotherapy (n = 38)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Thalidomide combined with chemotherapy (n = 25)
Number of subjects: 63
Study: 11602481

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave treatment (ESWT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simulated treatment (shocks of 0 mJ/mm(2) energy)
Number of subjects: 60
Study: 9810943

Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine injections
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine infusions
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine injections and infusions
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine
Number of subjects: 49
Study: 8206677

Group type: EXPERIMENTAL
Intervention: IL-2 (protocol 1, 40 patients)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: IL-2 plus interferon-gamma (IFN-gamma) (protocol 2, 33 patients)
Number of subjects: 73

Group type: COMPARATOR
Intervention: IL-2 alone (protocol 1)
Number of subjects: 73

Group type: COMPARATOR
Intervention: IL-2 plus IFN-gamma (protocol 2)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Pre-treatment sTNF-alpha R concentration
Number of subjects: 73
Study: 2919468

Group type: EXPERIMENTAL
Intervention: Copeland electrodes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spiral electrodes
Number of subjects: 0
Study: 31658624

Group type: EXPERIMENTAL
Intervention: m-Health intervention targeting physical activity, diet, and sleep quality
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 40
Study: 27725164

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice daily for 7 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 26342236

Group type: EXPERIMENTAL
Intervention: Molecularly targeted agents (experimental group)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Treatment at physician's choice (control group)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Cytotoxic chemotherapy (control group)
Number of subjects: 195
Study: 24292815

Group type: EXPERIMENTAL
Intervention: docetaxel, anthracycline, and cyclophosphamide (TEC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: docetaxel plus cyclophosphamide (TC)
Number of subjects: 96
Study: 21632605

Group type: EXPERIMENTAL
Intervention: Small priming dose of etomidate (0.03 mg kg(‐1))
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lipid emulsion placebo
Number of subjects: 80
Study: 19669786

Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail (AOC; vitamins C, E, and alpha-lipoic acid)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10 min forearm occlusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: 5 min forearm occlusion
Number of subjects: 14
Study: 16687511

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semantic dementia (SD) group
Number of subjects: 0
Study: 15219644

Group type: EXPERIMENTAL
Intervention: Fluoxetine (open label treatment for 6 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metyrapone challenge (evening)
Number of subjects: 20
Study: 11705814

Group type: EXPERIMENTAL
Intervention: Statin cerivastatin (HMG‐CoA reductase inhibitor)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with moderate hypercholesterolemia
Number of subjects: 30
Study: 9342964

Group type: EXPERIMENTAL
Intervention: Once-daily nitrate therapy
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Multiple-dose nitrate therapy
Number of subjects: 1212
Study: 8508698

Group type: EXPERIMENTAL
Intervention: Edrophonium chloride
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 14
Study: 3472492

Group type: EXPERIMENTAL
Intervention: Topical antibiotic applied to the anterior nares
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isotretinoin alone (Control)
Number of subjects: 18
Study: 29165837

Group type: EXPERIMENTAL
Intervention: Pulse width of 30 µs
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pulse width of 60 µs
Number of subjects: 15
Study: 27930448

Group type: EXPERIMENTAL
Intervention: Kettlebell swings (KBSs) with warm-up followed by 8 consecutive 20-second rounds of KBS with 10-second rest periods
Number of subjects: 60

Group type: COMPARATOR
Intervention: Warm-up alone (Control group)
Number of subjects: 60
Study: 26657793

Group type: EXPERIMENTAL
Intervention: Pragmatic Rehabilitation (PR)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Supportive Listening (SL)
Number of subjects: 296

Group type: COMPARATOR
Intervention: General Practitioner Treatment as Usual (Control)
Number of subjects: 296
Study: 23279972

Group type: EXPERIMENTAL
Intervention: Multicomponent knowledge-translation intervention (clinician education, paper-based VTE risk assessment algorithm, printed physicians' orders, audit and feedback sessions)
Number of subjects: 2611

Group type: COMPARATOR
Intervention: Usual care (no active strategies for thromboprophylaxis)
Number of subjects: 2611
Study: 21907756

Group type: EXPERIMENTAL
Intervention: Fluoridated milk (2.5 ppm, 5 ppm, 7.5 ppm, 10 ppm, 15 ppm, 20 ppm, 250 ppm) with 25 ml/section and 50 ml/section
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoridated milk (2.5 ppm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: De-ionized water and plain milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoridated milk (various concentrations)
Number of subjects: 0
Study: 18676140

Group type: EXPERIMENTAL
Intervention: Bec2 (2.5mg)/BCG vaccine arm (VA)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 515
Study: 16014329

Group type: EXPERIMENTAL
Intervention: Escitalopram 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12612296

Group type: EXPERIMENTAL
Intervention: Ro 25‐1553 (600 microg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Formoterol (4.5 microg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10853852

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.i.d.
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.i.d. plus ipratropium 40 microg q.i.d.
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.i.d. and Salmeterol 50 microg b.i.d. plus ipratropium 40 microg q.i.d.
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 9534284

Group type: EXPERIMENTAL
Intervention: Training program based on anaerobic threshold
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 8189744

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication at .10 breath alcohol concentration
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication at .05 breath alcohol concentration
Number of subjects: 48
Study: 3059851

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 15

Group type: COMPARATOR
Intervention: Both anaesthetics
Number of subjects: 15
Study: 31600930

Group type: EXPERIMENTAL
Intervention: Prudent diet
Number of subjects: 42

Group type: COMPARATOR
Intervention: Western diet
Number of subjects: 42
Study: 28251346

Group type: EXPERIMENTAL
Intervention: Ventriculoperitoneal (VP) shunt surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lumboperitoneal (LP) shunt surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shunt surgery for iNPH
Number of subjects: 0
Study: 25733175

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents with stent length < 20 mm
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents with stent length ≥ 20 mm
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Adjuvant post-dilatation
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Overall stent deployment
Number of subjects: 112
Study: 23182874

Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 0
Study: 21194775

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of nateglinide and GLP‐1 derivatives
Number of subjects: 0
Study: 18438905

Group type: EXPERIMENTAL
Intervention: Durometer measurements of skin hardness
Number of subjects: 43

Group type: COMPARATOR
Intervention: Modified Rodnan skin score (MRSS)
Number of subjects: 43
Study: 16495425

Group type: EXPERIMENTAL
Intervention: CPR only (N = 2,426)
Number of subjects: 6182

Group type: EXPERIMENTAL
Intervention: CPR+AED (N = 3,756)
Number of subjects: 6182

Group type: EXPERIMENTAL
Intervention: Testing and retraining for CPR skills
Number of subjects: 6182

Group type: EXPERIMENTAL
Intervention: Testing and retraining for CPR+AED skills
Number of subjects: 6182
Study: 14550939

Group type: EXPERIMENTAL
Intervention: Fluoxetine 10‐20 mg alone
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Estradiol patch 0.1‐0.2 mg alone
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Fluoxetine 10‐20 mg and estradiol patch 0.1‐0.2 mg (combination treatment)
Number of subjects: 5
Study: 12842676

Group type: EXPERIMENTAL
Intervention: Clear corneal incision (AcrySof IOL)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Scleral incision (PMMA IOL)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 123
Study: 10441772

Group type: EXPERIMENTAL
Intervention: Pharmaceutical treatment for osteoporosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dichotomized response based on predefined threshold
Number of subjects: 0
Study: 8537805

Group type: EXPERIMENTAL
Intervention: Albuterol 4 mg by mouth three times daily for 7 days
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104